Belgian medtech Nuclivision has secured €5M in a round co-led by LUMO Labs and Heran Partners, with participation from the imec.istart future fund.
The investment will support the commercial rollout of the company’s flagship AI software, Nuclarity, which enhances PET imaging efficiency while reducing both scan time and radiation exposure.
Founded in 2022, Nuclivision is part of a new wave of European deeptech startups applying AI to traditionally complex and costly healthcare procedures. The company’s technology specifically targets PET (positron emission tomography) scans, widely used in the diagnosis and treatment planning for diseases such as cancer and Alzheimer’s.
PET imaging is known for its diagnostic precision, enabling doctors to observe cellular-level activity. But it comes with downsides: the need for radioactive tracers and long scanning durations make the process expensive and raise health concerns. Nuclivision’s Nuclarity software addresses these issues by reducing the required dose of radiotracers and shortening scan times, without sacrificing image quality.
The company is currently in the final phase of regulatory approval and plans to launch its product in the European market, with an entry into the U.S. expected later this year.
“Medical imaging is at an inflection point,” said Nuclivision's CEO, Maarten Larmuseau. “With the rapid growth within radiopharma and theranostics, the use of AI and smart software is becoming necessary to handle the increased demand for PET and SPECT scans for conditions such as cancer and Alzheimer's.”
“Nuclivision is uniquely positioned in the field of AI-driven image enhancement for PET scans with the Nuclarity platform. By reducing the amount of time and the amount of costly and harmful radiotracers required for accurate medical imaging, Nuclarity not only reduces the time pressure on nuclear medicine departments but also the cost and harmful environmental and health impact of PET scans,” said Geoffrey D’hondt from Heran Partners.
“The completion of the regulatory approval process marks the beginning of a new growth phase for Nuclivision that is crucial for the actual deployment and impact of their technology,” explained Sven Bakkes, Founding Partner at LUMO Labs. “We look forward to supporting the founders and the growing team of Nuclivision in this, of course with indispensable growth capital but also with expertise and frameworks in the field of business operations and impact and with opening up our network.”
Kris Vandenberk, Managing Partner at imec.istart future fund, added: “We believe that Nuclivision can set a new standard in improving PET imaging. With seamless integration into hospital systems, the platform shows strong potential. We fully support the rollout of this platform.”
The intersection of AI and medical imaging has become one of the most active areas in healthtech, with applications ranging from radiology to pathology. In Europe, initiatives such as Horizon Europe and EU4Health have accelerated investment in health innovation and digitisation.
Would you like to write the first comment?
Login to post comments